Abstract

E2F1 (E2F transcription factor 1) can act as a tumor suppressor or oncogene. We report the molecular mechanism of E2F1 in ovarian carcinoma tumorigenesis and progression. E2F1 expression levels in ovarian carcinoma tissue were examined by immunohistochemistry. After E2F1 plasmid transfection and E2F1-microRNA-519d (miR-519d)/si-RhoC (Ras homolog gene family member C) co-transfection, ovarian cancer cell phenotypes and the related molecules were examined in vitro and in vivo. E2F1 was overexpressed in type I and type II ovarian carcinoma as compared to normal ovary tissues and normal fallopian tube tissues, respectively. E2F1 overexpression promoted cell proliferation, G1–S progression, survival, migration, and invasion in vitro; miR-519d or siRhoC co-transfection reversed E2F1 oncogenic effects. E2F1 overexpression promoted tumor growth in vivo; miR-519d overexpression inhibited it. E2F1 overexpression increased RhoC, Bcl-2, cyclin D1, survivin, MMP2 (matrix metalloproteinase 2), MMP9, STAT3 (signal transducer and activator of transcription 3), and HuR (ELAV-like RNA-binding protein 1) expression; miR-519d overexpression decreased their expression. E2F1 downregulated miR-519d directly and miR-519d downregulated RhoC directly. Conversely, miR-519d directly downregulated E2F1, There is a direct repressive regulatory loop between E2F1 and miR-519d. We provide evidence that E2F1/miR-519d/RhoC is a promising signaling pathway for diagnosing and treating ovarian carcinoma.

Highlights

  • Epithelial ovarian carcinoma is the most lethal gynecological malignancy, and has consistently low 5-year relative survival rates [1,2,3,4,5]

  • The findings suggest that E2F1 has potent oncogenic effects in ovarian carcinoma (Figure 1C, 1F) of different type and origin

  • We compared E2F1 expression levels in 59 cases of type I tumors and 17 normal ovarian tissues, and E2F1 expression was significantly elevated in the ovarian carcinoma tissues www.impactjournals.com/oncotarget www.impactjournals.com/oncotarget www.impactjournals.com/oncotarget and was positively associated with Federation of Gynecology and Obstetrics (FIGO) stage I–II and III–IV disease

Read more

Summary

Introduction

Epithelial ovarian carcinoma is the most lethal gynecological malignancy, and has consistently low 5-year relative survival rates [1,2,3,4,5]. Difficult early diagnosis and frequent recurrence and metastasis lead to the high mortality rate of epithelial ovarian carcinoma. Exploring the underlying molecular mechanisms of epithelial ovarian carcinoma is essential for developing effective diagnostic and treatment strategies. E2F1 suppresses gastric cancer by downregulating Bcl-2, cyclin D1, and survivin [17], and inhibits Hodgkin lymphoma by upregulating p53 expression [25]. It plays an oncogenic role by enhancing matrix metalloproteinase 9 (MMP9) transcription during invasion and metastasis in small cell lung cancer [28] and by activating MMP2 and MMP9 in local and vascular infiltration in clear cell renal cell carcinoma [29].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call